Protocol CY 5022: A PHASE 2, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, DOSE-RANGING, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF CK-2127107 IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Clinical Trial Grant
Administered By
Neurology
Awarded By
Cytokinetics, Inc.
Start Date
July 14, 2017
End Date
September 12, 2019
Administered By
Neurology
Awarded By
Cytokinetics, Inc.
Start Date
July 14, 2017
End Date
September 12, 2019